论文部分内容阅读
目的探讨经导管动脉免疫化疗栓塞(TAICE)治疗晚期肝癌患者的临床疗效。方法选取2013年8月至2015年8月间收治的60例晚期肝癌患者,按照随机数字表法随机分为观察组和对照组,每组30例。观察组患者给予TAICE治疗,对照组给予经导管动脉化疗栓塞(TACE)治疗,比较两组患者的临床疗效、免疫功能和不良反应发生率。结果观察组患者治疗有效率显著高于对照组,差异有统计学意义(P<0.05)。观察组患者血常规和肝功能检查结果与对照组比较,差异无统计学意义(P>0.05)。观察组患者CD3+、CD4+和CD4+/CD8+比值均显著高于对照组,差异均有统计学意义(均P<0.01)。两组患者不良反应发生率差异均无统计学意义(均P>0.05)。结论 TAICE治疗晚期肝癌临床疗效更优,且免疫功能更佳,具有临床应用价值。
Objective To investigate the clinical efficacy of transcatheter arterial chemoembolization (TAICE) in the treatment of advanced liver cancer. Methods Sixty patients with advanced liver cancer who were admitted between August 2013 and August 2015 were randomly divided into observation group and control group according to the random number table method, with 30 cases in each group. The patients in the observation group were treated with TAICE and the control group with transcatheter arterial chemoembolization (TACE). The clinical efficacy, immune function and incidence of adverse reactions in both groups were compared. Results The observation group patients treatment efficiency was significantly higher than the control group, the difference was statistically significant (P <0.05). There was no significant difference between the observation group and the control group in blood test and liver function test (P> 0.05). The ratio of CD3 +, CD4 + and CD4 + / CD8 + in the observation group was significantly higher than that in the control group (all P <0.01). There was no significant difference in the incidence of adverse reactions between the two groups (all P> 0.05). Conclusion TAICE has better clinical efficacy and better immune function in the treatment of advanced liver cancer, and has clinical value.